This federal Project Grant award from the National Institutes of Health (NIH) Trans-NIH Research Support program (CFDA 93.310) provides $192,500 to the University of Tennessee Health Science Center to evaluate the feasibility of inhibiting the enzyme microsomal prostaglandin E synthase-1 (mPGES-1) as a potential delayed countermeasure against the long-term neurotoxicity and behavioral impacts caused by exposure to organophosphate nerve agents. The goal is to establish proof-of-concept for mPGES-1 inhibition as an effective strategy to mitigate the neurological sequelae of cholinergic receptor hyperstimulation triggered by organophosphate agents. The project runs from June 2024 through May 2026 and will inform future studies on lead optimization, efficacy, safety, and combination treatments for addressing the long-term neurotoxicity and functional deficits associated with organophosphate exposure.
Generated 1/28/25, 8:40 AM